Shares of Hims & Hers Health Inc. (NYSE: HIMS) surged 6.65% in after-hours trading on Monday following the release of its impressive third-quarter 2025 financial results and news of potential collaboration with Novo Nordisk for weight loss treatments.

The telehealth company reported Q3 revenue of $600 million, significantly beating analyst expectations of $579.3 million. Earnings per share came in at $0.06, while net income reached $16 million. The strong performance was driven by a 21% year-over-year increase in subscribers to 2.47 million and a 19% rise in monthly online revenue per average subscriber to $80.

Adding to investor optimism, Hims & Hers raised its full-year 2025 revenue guidance to between $2.335 billion and $2.355 billion, up from previous estimates. The company also revealed it is in active discussions with Novo Nordisk to make Wegovy injections and Novo Nordisk's oral Wegovy (pending FDA approval) available through the Hims & Hers platform. This potential partnership could significantly expand the company's offering in the booming weight loss market, though no definitive agreement has been reached yet.